![conference banner](/images/conference-banner.jpeg)
Abstract
Background: 6-MP has short elimination time (<2 h) and low bioavailability (~ 50%). Present study was aimed to develop time controlled and site targeted delivery of 6-Mercaptopurine (6-MP) for treatment of colon diseases.
Methods: Compression coating technique was used. 32 full factorial design was designed for optimization of the outer coat for the core tablet. For outer coat amount of Eudragit RS 100 and hydroxypropyl methylcellulose (HPMC K100) were employed as independent variables each at three levels while responses evaluated were swelling index and bursting time. Direct compression method was used for tablets formulation.
Results: 80% w/w of microcrystalline cellulose and 20% w/w of croscarmellose sodium were found to be optimum concentration for the core tablet. The outer coat of optimized batch (ED) contains 21.05% w/w Eudragit RS 100 and 78.95% w/w HPMC K100 of total polymer weight. In-vitro dissolution study indicated that combination of polymer retards the drug release in gastric region and releases ≥95% of drug in colonic region after ≥7 h. Whereas in case of in-vivo placebo x-ray imaging study had shown that the tablet reaches colonic part after 5±0.5 h providing the proof of arrival in the colon. Stability study indicated that the optimized formulation were physically and chemically stable.
Conclusion: Present research work concluded that compression coating by Eudragit RS 100 and HPMC K100 to 6-MP core provides potential colon targeted system with advantages of reduced gastric exposure and enhanced bioavailability. Formulation can be considered as potential and promising candidate for the treatment of colon diseases..
Keywords: Cancer, colon, compression coating, eudragit RS 100, HPMC K100, 6-Mercaptopurine.
Current Drug Delivery
Title:Optimization of Time Controlled 6-mercaptopurine Delivery for Site- Specific Targeting to Colon Diseases
Volume: 13 Issue: 4
Author(s): Rahul U. Hude and Swati C. Jagdale
Affiliation:
Keywords: Cancer, colon, compression coating, eudragit RS 100, HPMC K100, 6-Mercaptopurine.
Abstract: Background: 6-MP has short elimination time (<2 h) and low bioavailability (~ 50%). Present study was aimed to develop time controlled and site targeted delivery of 6-Mercaptopurine (6-MP) for treatment of colon diseases.
Methods: Compression coating technique was used. 32 full factorial design was designed for optimization of the outer coat for the core tablet. For outer coat amount of Eudragit RS 100 and hydroxypropyl methylcellulose (HPMC K100) were employed as independent variables each at three levels while responses evaluated were swelling index and bursting time. Direct compression method was used for tablets formulation.
Results: 80% w/w of microcrystalline cellulose and 20% w/w of croscarmellose sodium were found to be optimum concentration for the core tablet. The outer coat of optimized batch (ED) contains 21.05% w/w Eudragit RS 100 and 78.95% w/w HPMC K100 of total polymer weight. In-vitro dissolution study indicated that combination of polymer retards the drug release in gastric region and releases ≥95% of drug in colonic region after ≥7 h. Whereas in case of in-vivo placebo x-ray imaging study had shown that the tablet reaches colonic part after 5±0.5 h providing the proof of arrival in the colon. Stability study indicated that the optimized formulation were physically and chemically stable.
Conclusion: Present research work concluded that compression coating by Eudragit RS 100 and HPMC K100 to 6-MP core provides potential colon targeted system with advantages of reduced gastric exposure and enhanced bioavailability. Formulation can be considered as potential and promising candidate for the treatment of colon diseases..
Export Options
About this article
Cite this article as:
U. Hude Rahul and C. Jagdale Swati, Optimization of Time Controlled 6-mercaptopurine Delivery for Site- Specific Targeting to Colon Diseases, Current Drug Delivery 2016; 13 (4) . https://dx.doi.org/10.2174/1567201812666150317123226
DOI https://dx.doi.org/10.2174/1567201812666150317123226 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-Based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access to both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Extracellular vesicles as drug delivery systems
Extracellular vesicles (EVs) are membranous vesicles released from almost all types of cells into extracellular space. EVs are categorized into different types including exosome (~30-150 nm), microvesicle or microparticle (~100-1,000 nm), apoptotic body (~1,000-5,000 nm), and others produced by different mechanisms. Since EVs bear the molecules (e.g., specific lipids, carbohydrates, ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Low Molecular Weight Compounds with Transition Metals as Free Radical Scavengers and Novel Therapeutic Agents
Cardiovascular & Hematological Agents in Medicinal Chemistry Selective Chemokine Receptor-Targeted Depletion of Pathological Cells as A Therapeutic Strategy for Inflammatory, Allergic and Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Corneal Neovascularization: Molecular Events and Therapeutic Options
Recent Patents on Inflammation & Allergy Drug Discovery Chemokine-Chemokine Receptor Network in Immune Cell Trafficking
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Investigation of the Effect of <i>Prunus Amygdalus</i> Amara on the Expression of some Genes of Apoptosis and Immortality in Breast Cancer Cells (MCF- 7)
Current Drug Research Reviews PET Tracers Based on Zirconium-89
Current Radiopharmaceuticals Seq and You Will Find
Current Gene Therapy Alpha1-Antitrypsin Deficiency: Transition of Care for the Child With AAT Deficiency into Adulthood
Current Pediatric Reviews Interaction of Mesalasine (5-ASA) with Translational Initiation Factors eIF4 Partially Explains 5-ASA Anti-Inflammatory and Anti-Neoplastic Activities
Medicinal Chemistry Recent Advances in Protein and Peptide Drug Delivery: A Special Emphasis on Polymeric Nanoparticles
Protein & Peptide Letters Potential Value of the Stretched Exponential and Fractional Order Calculus Model in Discriminating Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: An Animal Experiment of Orthotopic Xenograft Nude Mice
Current Medical Imaging Therapeutic Significance of Cornin in Medicine for Their Biological Importance and Pharmacological Activity: An Overview of Iridoid Glycosides of <i>Verbena Officinalis L.</i>
Current Functional Foods Physiology and Pharmacology of the Vanilloid Receptor
Current Neuropharmacology Tolerance in Intestinal Inflammation and Cancer
Current Drug Targets Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Current Innovations in Laparoscopy
Current Women`s Health Reviews Advancement in Obesity Management: Leptin and Adiponectin Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Computed Tomographic Evaluation of Colonic Diverticulum Complications
Current Medical Imaging Learning from Metabolic Networks: Current Trends and Future Directions for Precision Medicine
Current Medicinal Chemistry Current Management of Neonatal Liver Tumors
Current Pediatric Reviews